- Home
- CRIS vs INAB Comparison
CRIS vs INAB Comparison
Compare CRIS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | INAB |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 14.2M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRIS | INAB |
|---|---|---|
| Price | $0.69 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $6.00 |
| AVG Volume (30 Days) | ★ 496.7K | 70.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.49 | $0.12 |
| 52 Week High | $3.13 | $4.20 |
Technical Indicators
Market Signals| Indicator | CRIS | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 40.39 |
| Support Level | N/A | $1.35 |
| Resistance Level | $1.04 | $2.14 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 64.94 | 33.33 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.